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Summary
Apoptosis resistance commonly occurs in cancers, preventing activation of Caspase family cell death proteases. XIAP is
an endogenous inhibitor of Caspases overexpressed in many cancers. We developed an enzyme derepression assay,
based on overcoming XIAP-mediated suppression of Caspase-3, and screened mixture-based combinatorial chemical
libraries for compounds that reversed XIAP-mediated inhibition of Caspase-3, identifying a class of polyphenylureas with
XIAP-inhibitory activity. These compounds, but not inactive structural analogs, stimulated increases in Caspase activity,
directly induced apoptosis of many types of tumor cell lines in culture, and sensitized cancer cells to chemotherapeutic
drugs. Active compounds also suppressed growth of established tumors in xenograft models in mice, while displaying
little toxicity to normal tissues. These findings validate IAPs as targets for cancer drug discovery.
Introduction Moreover, some tumor cells constitutively activate Caspases,
apparently offsetting Caspases with overexpression of IAP fam-
At a fundamental level, cancer occurs or progresses because ily proteins (Yang et al., 2003a). Thus, small-molecule drugs
malignant cells fail to undergo apoptosis either spontaneously that inhibit IAPs could be therapeutically useful in the treatment
or in response to chemotherapy. Failure to activate Caspases of malignancy.
may account for resistance to apoptosis. Caspases are a family XIAP is the best characterized of the IAP family members
of intracellular cysteine proteases that trigger the apoptotic pro- in terms of its Caspase inhibitory mechanism. The XIAP protein
gram (Cryns and Yuan, 1999; Thornberry and Lazebnik, 1998). contains three BIR domains. BIR2 and flanking regions are re-
Caspases lie in a latent (zymogen) state in cells but become sponsible for binding and potently inhibiting active Caspases-3
activated in response to a wide variety of cell death stimuli. and -7, while BIR3 and flanking regions suppress Caspase-9
The Inhibitor of Apoptosis Proteins (IAPs) represent a family (Deveraux et al., 1999; Takahashi et al., 1998). XIAP levels are
of endogenous Caspase inhibitors that share a conserved struc-
pathologically elevated in many acute and chronic leukemias,
ture known as the BIR domain (Reed, 2001). Eight IAP-encoding
prostate cancers, lung cancers, and other types of tumors (Byrdgenes are found in the human genome, and some of these are
et al., 2002; Ferreira et al., 2001; Hofmann et al., 2002; Krajewskaoverexpressed in cancers (Ferreira et al., 2001; Hofmann et
et al., 2003; Schimmer et al., 2003; Tamm et al., 2000). Here,al., 2002; Tamm et al., 2000). Various proof-of-concept studies
we describe the generation and characterization of prototypeusing antisense oligonucleotides or peptide inhibitors of IAP
small-molecule antagonists of XIAP targeting BIR2 that inducehave suggested that these proteins are important for maintaining
apoptosis of tumor cells in culture and that display antitumortumor cell survival or for affording resistance to apoptosis induc-
activity in vivo. The findings validate certain IAP family proteinstion by anticancer drugs (Bilim et al., 2003; Fulda et al., 2002;
Gordon et al., 2002; Sasaki et al., 2000; Yang et al., 2003b). as suitable targets for cancer drug discovery.
S I G N I F I C A N C E
Inhibitor of Apoptosis Proteins (IAPs) are a family of apoptosis-suppressing proteins commonly overexpressed in human cancers.
Some IAPs directly bind and suppress Caspases, the proteases responsible for apoptosis. We generated chemical compounds that
target the BIR2 domain of XIAP. These compounds triggered apoptosis of most types of tumor cell lines and primary leukemias in
culture. Active compounds also inhibited tumor growth in mice, while producing little toxicity to normal tissues. The findings suggest
that cancer cells have an intrinsic drive to apoptosis that is held in check by IAPs. Negating IAPs allows the apoptosis program to
proceed. Normal cells appear to be less dependent on IAPs, thus providing the basis for a therapeutic index.
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Figure 1. Identification of small-molecule XIAP in-
hibitors by screening combinatorial mixture-
based libraries
A: Mixture-based combinatorial library of poly-
phenylureas was constructed in positional scan-
ning format by fixing the functionality at the R1,
R2, or R3 position and combining into the mixture
the variations of the other diversity groups. These
mixture-based libraries were screened using the
Caspase derepression assay for chemicals that
overcome XIAP-mediated repression of Cas-
pase-3. Aliquots from the mixtures were added to
microtiter plates containing XIAP and Caspase-3
(black bars) or, as a control, Caspase-3 alone
(gray bars). Caspase-3 activity was measured by
monitoring cleavage of the fluorogenic sub-
strate Ac-DEVD-AFC. Hits were empirically de-
fined as compounds that increased Caspase-3
activity 2-fold in XIAP-inhibited reactions with-
out affecting Caspase-3 alone. A representative
screen of the positional scanning combinatorial
library (final concentration 25 g/ml) is shown.
Caspase activity is presented as the fold in-
crease in enzyme velocity after the addition of
the compound.
B: Individual compounds were synthesized
based on deconvolution of the polyphenylurea
library. Thirty-six individual compounds were
tested at 25 g/mL using the Caspase derepres-
sion assay for their ability to increase Caspase-3
activity in the presence (black bars) or absence
(gray bars) of XIAP, using a 2-fold elevation in
the enzyme velocity as the cut-off for positivity.
Results activity 2-fold when applied to XIAP/Caspase-3 assays with-
out affecting Caspase-3 alone. The positive compound mixtures
were then deconvoluted by standard methods (Pinilla et al.,Identification and characterization of small-molecule
antagonists of XIAP 1992, 2003), yielding 36 individual compounds, which were
screened in the same enzyme derepression assay, resulting inBased on the knowledge that XIAP directly inhibits active Cas-
pase-3, we devised an enzyme derepression assay in which the identification of eight compounds that increased Caspase-3
activity in XIAP-inhibited reactions by2-fold (Figure 1B) (struc-libraries of chemical compounds were screened for molecules
that relieve protease inhibition, allowing Caspase-3 to cleave tures are provided in Table S1 of the Supplemental Data [http://
www.cancercell.org/cgi/content/full/5/1/25/DC1]). In the processa fluorogenic peptide substrate. Eleven mixture-based small-
molecule combinatorial libraries (constituting approximately one of library deconvolution, we also identified compounds such as
1396-28 that differed from active molecules at R1, R2, or R3 andmillion compounds) were screened, including a library of poly-
phenylureas (Nefzi et al., 2000) synthesized in the positional which did not inhibit XIAP (EC50  100 uM), serving as controls
for subsequent experiments.scanning format (Pinilla et al., 1992). All compounds in this
particular chemical library shared a common polyphenylurea To determine the specificity of the active compounds, we
compared their effects on inhibition of Caspase-3, -7, and -9scaffold with three diversity positions (R1, R2, and R3), where 48
different chemical moieties were linked at the R1 and R2 positions by XIAP. Figure 2 shows representative data for four active
compounds (1396-11, 12, 22, and 34) and negative controland 39 at the R3 position, thus constituting a library of 135
mixtures and a total of 89,856 compounds (Figure 1A). Thus, (1396-28). Whereas all active compounds restored Caspase-3
and Caspase -7 activity toward normal, none of the compoundsthree sublibraries based on the location of the defined position
(R1, R2, or R3) and composed of mixtures having a fixed chemical reversed XIAP-mediated suppression of Caspase-9 (Figures 2A
and 2B and data not shown). Since it is known that the BIR2moiety at one of the positions were used to screen for XIAP
inhibitors. Each mixture was screened for its effects on Cas- domain and an upstream flanking segment of XIAP are sufficient
to inhibit Caspases-3 and -7, we tested whether the activepase-3 activity in the presence and absence of XIAP, scoring
as a “hit” those compound mixtures that increased Caspase-3 compounds could relieve Caspase suppression mediated by
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Figure 2. Character izat ion of biochemical
mechanism of polyphenylurea XIAP antagonists
Four active XIAP antagonists (1396-11, 1396-12,
1396-22, 1396-34) or inactive control (1396-28)
were added in excess (75 M) to enzyme dere-
pression assays containing (A) 46 nM full-length
recombinant XIAP and 0.36 nM active Caspase-
3; (B) 46 nM full-length XIAP and 2.2 nM active
Caspase-9 (lacking its N-terminal CARD domain);
(C) 1.2 nM GST-BIR2 fragment of XIAP and 0.36
nM active Caspase-3. (D) 3.4 nM recombinant
baculovirus p35 and 0.36 nM active Caspase-3.
Caspase activity was measured either by hydro-
lysis of Ac-DEVD-AFC (Caspase-3 substrate [A, C,
and D]) or Ac-LEHD-AFC (Caspase-9 substrate
[B]). Data represent enzyme velocity relative to
XIAP-inhibited reactions in the absence of com-
pound ( 1.0), where ratio of the enzyme rates
with compound versus without compound are
provided (mean  SE [n  3]). (E) Biotinylated
SMAC (7 mer) was adsorbed to Neutravidin-
coated plates, then GST-XIAP was added with or
without compound or tetrapeptides, detecting
bound GST-XIAP with anti-GST antibody. (F) GST-
XIAP was adsorbed to plates and then incu-
bated with biotinylated-SMAC (7 mer) with or
without chemical compounds or SMAC hepta-
peptide, detecting bound biotinylated-SMAC
peptide by a streptavidin-europium-based fluo-
rescence method (mean  SE; n  3).
a GST-BIR2 fusion protein (Takahashi et al., 1998). All active was incubated with adsorbed XIAP in the presence or absence
of candidate inhibitors, detecting plate-bound biotin-SMACcompounds restored Caspase-3 activity toward normal in BIR2-
suppressed reactions (Figure 2C). NMR-based binding assays using streptavidin-europium in conjunction with a fluorescence-
based method (Figure 2F). Thus, these polyphenylurea antago-also showed that active (but not inactive) analogs of the com-
pounds directly bind purified recombinant BIR2 of XIAP but not nists of XIAP act through a mechanism distinct from endoge-
nous XIAP antagonist SMAC.control proteins (our unpublished data). Dose-response studies
performed for these four XIAP antagonists revealed EC50 values
of 32–58 M against full-length XIAP versus 5–22 M against XIAP inhibitors induce Caspase activation
and apoptosis of tumor cellsBIR2 (EC50  concentration required to restore Caspase activity
to half-maximal rate). In contrast, the compounds did not over- To evaluate the effects of our small-molecule XIAP inhibitors in
cells, we incubated cultured tumor cell lines with active andcome Caspase-3 suppression by p35 (Figure 2D), a viral inhibitor
of Caspases with a mechanism of inhibition unrelated to IAPs (Xu structurally similar inactive polyphenylureas and measured cell
viability at various times thereafter. Multiple tumor cell lineset al., 2001), thus confirming their specificity. These compounds
also did not show activity in other types of biochemical assays were thus empirically determined to be sensitive to these XIAP
antagonists, undergoing apoptosis when incubated with active(e.g., luciferase activity; Bcl-XL binding to BH3 peptides), again
confirming a specific effect. but not inactive polyphenylurea-based compounds. Figure 3A
shows representative data using Jurkat leukemia cells. For theseTo further explore the mechanism of these small-molecule
antagonists of XIAP, we performed binding assays, testing experiments, Jurkat cells were treated for 20 hr with increasing
concentrations of five of the most potent XIAP inhibitors (1396-whether these compounds compete for interactions with the
same sites on BIR domains that are targeted by certain endoge- 10, 11, 12, 22, 34) and compared with five inactive structural
analogs (1396-13, 14, 16, 28, 31) (for structures, see Tablenous inhibitors of XIAP, such as SMAC and HtrA2 (Liu et al.,
2000; Suzuki et al., 2001). Accordingly, streptavidin was ad- S1 of the Supplemental Data [http://www.cancercell.org/cgi/
content/full/5/1/25/DC1]). Cells were also treated with thesorbed to plates, biotin-SMAC peptide was bound, and then
GST-XIAP was incubated in the presence or absence of candi- SMAC tetrapeptide (AVPI) for comparison. After incubation,
dead cells were identified by Annexin-V staining. All of the com-date inhibitors, followed by detection with anti-GST antibody.
As shown in Figure 2E, SMAC 4-mer peptide AVPI effectively pounds that displayed XIAP-inhibitory activity in the in vitro
enzyme derepression assay induced apoptosis of Jurkat leuke-competed with biotin-SMAC for binding to XIAP, while mutant
peptide GVPI did not. In contrast, none of our XIAP-inhibitory mia cells in a dose-dependent manner, with the concentration
required for killing half the cells (lethal dose-50%; LD50) of 6–17polyphenylureas competed with biotin-SMAC (Figure 2E and
data not shown). Similar results were obtained using an alterna- M. In contrast, none of the inactive structural analogs killed
Jurkat cells, at concentrations up to 50 M. Similar resultstive binding assay where GST-XIAP was adsorbed to 96-well
plastic plates, then biotinylated SMAC 7-mer peptide (AVPIAQK) were obtained for several other cancer cell lines (see below). In
CANCER CELL : JANUARY 2004 27
A R T I C L E
Figure 3. Characterization of cellular activity of polyphenylurea XIAP antagonists
A: Jurkat leukemia cells were cultured for 20 hr with various concentrations of either active (top) (1396-10, 11, 12, 22, 34) or inactive (bottom) (1396-13, 14,
16, 28, 31) polyphenylureas. SMAC tetrapeptide (AVPI) was also included in the study. The percentage of dead cells was determined by annexin-V staining.
B: Jurkat cells were cultured with 10 M 1396-34 for various times before measuring percentage cell death by annexin-V staining (mean  SE; n  3).
C: Jurkat cells were cultured with the XIAP antagonist 1396-34, the structurally related control compound 1396-28, or SMAC 4-mer AVPI peptide at final
concentrations of 8 M for 20 hr. After incubation, Caspase-3/7 activity was measured in whole cells using a cell-permeable substrate. Data represent fold
increase relative to untreated cells (mean  SD; n  3).
D: Jurkat cells were cultured with various concentrations of XIAP antagonists 1396-34 with (solid line) or without (dashed line) 100 M zVAD-fmk. Percentage
cell death was measured 20 hr later by annexin-V staining (mean  SD; n  3).
E: U937 cells stably overexpressing XIAP (squares) or neomycin control transfectants (diamonds) were cultured with various concentrations of the XIAP
inhibitor 1396-34 for 20 hr. Percentage cell death was measured by annexin-V staining. Inset shows immunoblot analysis of lysates prepared from the U937
cells. Samples were normalized for total protein content and analyzed by SDS-PAGE/immunoblotting using antibodies specific for XIAP, Pro-Caspase-3,
and -Actin. Note that differences in antibody affinities and blot exposure times preclude quantitative comparisons of the ratio of XIAP:Pro-Caspase-3.
F: HeLa cells were transfected with plasmids encoding XIAP, Bcl-XL Crm A, or empty vector. At 2 days after transfection, cells were treated with the XIAP
antagonist 1396-34 (5 M) for 20 hr, then percentage dead cells was measured by annexin-V staining (mean  SD; n  3).
G: Cultures of mouse embryo fibroblasts (MEFs) were established and either tested directly at low passage (left panels) or after transformation by infection
with a retrovirus encoding SV40 large T antigen (right panels). Cells were cultured for 1 day with various concentrations of active compound 1396-34. Cell
viability was measured by MTT assay, expressing data as a percentage relative to control, untreated cells. Data represent mean  SD of triplicate
determinations. Death of xiap/ MEFs remained 10% above background for up to 3 days in cultures containing 5 M 1396-34 (data not shown).
contrast to BIR2-targeting phenylureas, SMAC 4-mer also failed dose-response curve among XIAP-suppressing compounds
may reflect subtle differences in their stability, cell permeability,to kill Jurkat cells, possibly due to poor cell permeability. We
therefore tested the effects of a SMAC peptide containing a serum protein binding, metabolism, or activity against other IAP
family members besides XIAP.polyarginine (membrane-penetrating) sequence (SMAC-Arg8),
but it also failed to induce apoptosis of Jurkat leukemia cells The kinetics of apoptosis induction of Jurkat cells by XIAP
antagonists such as 1396-34 was rapid, with half-maximal killingat concentrations up to 50 M (data not shown).
Among 18 compounds tested based on the polyphenylurea achieved at approximately 12 hr and maximum killing at 24
hr (Figure 3B). As expected, XIAP antagonists such as 1396-pharmacophore, none were identified that induced apoptosis
of cancer cells that were inactive in the in vitro Caspase dere- 34 induced Caspase activation, while inactive compounds such
as 1396-28 (which differs from 1396-34 only at R2) did notpression assay. Conversely, none were identified that were
active in the Caspase derepression assay but inactive in the (Figure 3C). The apoptosis induced by these compounds was
suppressible by coculturing the cells with a broad spectrumcell-based assay. Differences in the shape of the cytotoxicity
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Caspase inhibitor, zVAD-fmk (Figure 3D), consistent with their
intended mechanism.
Consistent with IAPs representing the primary target of the
polyphenylureas described here, transient or stable overexpres-
sion of XIAP rendered tumor cell lines more resistant to apopto-
sis induction by active compounds, shifting the dose-response
curve to the right, so that higher concentrations of compound
were required (Figure 3E). In contrast, overexpressing antiapo-
ptotic proteins Bcl-XL or CrmA did not alter sensitivity of tumor
cell lines to the XIAP antagonists (Figure 3F), demonstrating a
specific effect. Bcl-XL overexpression however did afford resis-
tance to traditional anticancer drugs such as etoposide, and
CrmA (a Caspase-8 inhibitor) (Zhou et al., 1997) protected cells
from apoptosis induced by TRAIL (data not shown), confirming
that these antiapoptotic proteins were functional in these experi-
ments.
To further address the mechanism of these compounds,
we tested their activity against normal and transformed mouse
embryo fibroblasts (MEFs) derived from wild-type (xiap	/	) ver-
sus knockout (xiap/) mice (gift of C. Duckett) (Harlin et al.,
2001). XIAP antagonists such as 1396-34 displayed greater cy-
totoxic activity against transformed xiap	/	 than xiap/ cells,
consistent with mechanism-based activity (Figure 3G). If these
compounds killed cells through a nonspecific mechanism, we
would expect to observe more apoptosis rather than less apo-
ptosis in XIAP-deficient cells. Interestingly, transformed MEFs
displayed greater sensitivity to XIAP antagonists than normal
cells (Figure 3G). In contrast to XIAP antagonists, the conven-
tional anticancer drug daunorubicin was equally cytotoxic
against normal and transformed MEFs and against xiap	/	 and
xiap/ cells (Figure S1 [http://www.cancercell.org/cgi/content/
full/5/1/25/DC1]). Unlike conventional cytotoxic anticancer
drugs, polyphenylurea XIAP antagonists also displayed little cy-
totoxic activity against normal cultured rat hepatocytes, human
epithelial cells, or bone marrow cells at concentrations10 M
(Figure S2 and data not shown).
Broad activity of XIAP antagonists against tumor cell
lines and leukemia cells
To assess the spectrum of apoptotic activity of IAP antagonists, Figure 4. Broad antitumor activity of XIAP antagonists
we tested selected polyphenylureas on the NCI panel of 60 human A: Sixty human tumor cell lines were cultured with various concentrations
tumor cell lines (Figure 4A and Figure S3 [http://www.cancercell. of active XIAP antagonist 1396-34 or inactive control 1396-28 for 2 days,
then relative cell numbers were determined by a protein-based colorimetricorg/cgi/content/full/5/1/25/DC1]). All of these tumor cell lines
assay, expressing data as percentage growth relative to cells treated withwere previously shown to express endogenous XIAP protein
solvent control alone. Each line represents a tumor line.
(Tamm et al., 2000). Cells were cultured with these compounds B: CLL B cells from five patients were cultured with various concentrations
for 48 hr, followed by measurement of the relative number of of active polyphenylureas 1396-11, 12, or 34 or with inactive polyphenylurea
1396-28 (negative control). After 1 day, the percentage of apoptotic cellsviable cells (Alley et al., 1988). The XIAP inhibitors 1396-11,
was determined by annexin-V/propidium iodide staining, with FACS analysis.1396-12, 1396-22, and 1396-34 induced reductions in viable
Data represent mean  SE for n  5.cell numbers, with an average LD50 for the 60 cell lines of 10  C: AML cells were isolated from peripheral blood of five patients and cul-
2.8 M (median 17 M), 7.6 12 M (median 6 M), 11 tured with various concentrations of polyphenylurea IAP antagonist 1396-
2.6 M (median  22 M), and 22  5 M (median  23 M), 34. Percentage cell death was measured 1 day later by annexin-V staining.
All samples were treated with both active (1396-34) and inactive (1396-28)respectively. Moreover, the LD50 was 
10 M for over one-
polyphenylurea as well as AVPI peptide, but the complete data set is shownthird of the tumor cells treated with the active compounds. In
only for AML-1. Comparable results were obtained with control compound
contrast, LD50 was not reached for any of the 60 tumor cell lines for the other leukemia specimens.
after treatment with up to 70 M of the structurally related
control compound 1396-28 (Figure 4A). By comparison, when
using this same assay, the mean LD50 for the anticancer drug
etoposide in the NCI 60 cell panel is 200  2.5 M, with none XIAP-inhibitory compounds compares favorably with drugs cur-
of cells having LD50 
10 M, and the LD50 for doxorubicin is rently used in the treatment of cancer.
12 M (http://dtp.nci.nih.gov) (Table S2 [http://www.cancercell. Since many tumor and leukemia cell lines proliferate faster
than normal cells, we explored whether XIAP antagonists couldorg/cgi/content/full/5/1/25/DC1]). Thus, the potency of these
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orubicin (DOX), and Paclitaxel (TAXOL). Similar results were ob-
tained for PC3 and PPC1 prostate cancer cells treated with
VP16, DOX, or TAXOL and for H460 lung cancer cells treated
with VP16 or DOX (Figure S5 [http://www.cancercell.org/cgi/
content/full/5/1/25/DC1]). Inactive polyphenylureas failed to
sensitize tumor cells to anticancer drugs (data not shown).
We similarly tested the effects of XIAP antagonists on apo-
ptosis induction by the biological agent TRAIL, an apoptosis-
inducing member of the Tumor Necrosis Factor (TNF) family
(Ashkenazi and Dixit, 1998). Prototype XIAP antagonist 1396-
34 sensitized PPC1, ALVA31, Du145, and HeLa cells to TRAIL-
induced apoptosis (Figure 5B and data not shown). Inactive
control compounds did not display this activity (data not shown).
Clonogenic survival of cancer cells is reduced
by XIAP antagonists
In addition to short-term cytotoxicity assays, selected XIAP an-Figure 5. IAP antagonists sensitize cancer cells to chemotherapy and TRAIL
tagonists were tested for effects on clonogenic survival of can-A: Du145 prostate cancer cells were cultured for 48 hr with various concen-
cer cells in colony formation assays, often considered a moretrations of Etoposide (VP16), Doxrubicin (DOX), or Paclitaxel (TAXOL), with
(	) or without () 10 M XIAP antagonist 1396-34. The percentage of viable stringent test of anticancer activity. Figure 6A shows data from
cells relative to control was determined by MTT assay (mean 	 SE; n  3). two prostate cancer cell lines arbitrarily chosen for testing. Pro-
B: Alternatively, cancer cell lines were treated with various concentrations
totype XIAP antagonist 1396-34 diminished clonogenic survivalof TRAIL alone (dashed line) or in combination with (solid line) IAP antagonist
of these cancer lines in a concentration-dependent manner,1396-34 at 1M. Control compounds did not affect sensitivity to chemother-
apy or TRAIL (data not shown). with an average EC50 dose of 3 M  0.5 M (mean  SE). At
a dose of 10 M, colony formation was reduced to 
5% of
control, in contrast to inactive control compounds which had
relatively little effect (Figure 6).
induce apoptosis of nonreplicating malignant cells. Accordingly,
freshly isolated chronic lymphocytic leukemia (CLL) B cells from
XIAP inhibitors are effective in tumor xenograft models
five patients and freshly isolated leukemic blasts from five pa-
Selected IAP antagonists were tested for antitumor activity intients with acute myelogenous leukemia (AML) were treated for
vivo, using human tumor xenografts grown in immunocomprom-20–24 hr in vitro with the XIAP inhibitors 1396-11, 1396-12, or
ised mice. First, we explored what doses of IAP-inhibitory com-1396-34 versus 1396-28 control compound or AVPI peptide,
pounds were tolerated by mice, finding that 200–400 mg/kgand the percentage of cell death was measured by annexin-V
delivered i.p. as a single or in divided doses resulted in no grossstaining (Figures 4B and 4C). These leukemic cell samples con-
toxicity. Then, for tumor xenograft studies, PPC1 prostate ortained only small percentages of cycling cells and did not repli-
HCT116 colon cancer cells were injected subcutaneously intocate under standard culture conditions. XIAP antagonists in-
the flanks of Balb/c nu/nu mice, measuring tumor volume exter-duced dose-dependent cell death of primary-cultured leukemia
nally with calipers and sacrificing mice 19–24 days after tumorcells in 5 of 5 CLL (Figure 4B) and 4 of 5 AML (Figure 4C)
inoculation to weigh excised tumors. Tumors were allowed tospecimens examined, with LD50 achieved at doses of approxi-
grow for 6–7 days (when tumor were 125 mm3), then micemately 5 M after correction for spontaneous apoptosis in cul-
were dosed with 30 mg/kg i.p. of either solvent diluent (control)ture. In contrast, the inactive control compound 1396-28 and
or XIAP antagonists 1396-34 (Figures 6B and 6C) or 1396-22AVPI peptide did not induce apoptosis of these leukemia cells.
(data not shown), repeating the dosing the next day (2 dayThe membrane-penetrating SMAC-Arg8 peptide also failed
treatment) or for two additional days (3 day treatment). Dosingto induce apoptosis of primary CLL cells (Figure S4 [http://
mice for just 2 or 3 days with XIAP antagonist 1396-34 or 1396-www.cancercell.org/cgi/content/full/5/1/25/DC1]). Thus, cell repli-
22 significantly slowed the rate of growth of both PPC1 andcation is not required for sensitivity to BIR2-targeting poly-
HCT116 tumors, thus demonstrating in vivo antitumor activityphenylurea XIAP antagonists.
of these chemical compounds.XIAP antagonists were also active against transformed he-
Analysis of tumor tissue from mice treated with XIAP antago-matopoietic cells from mice, inducing death of mouse 70Z/3
nists showed evidence of proteolytic processing of Caspaseslymphoma and immortalized 32D myeloid cells with EC50 values
and Caspase substrates (Figure 6D), as well as histologicalof 8–12 M (data not shown).
evidence of tumor regression by apoptosis (Figures 6D and 6E).
XIAP antagonists did not appear to alter tumor cell proliferation,XIAP antagonists sensitize tumor cells to anticancer
as judged by PCNA immunostaining. In contrast to tumor tis-drugs and TRAIL
sues, normal tissues such as liver, kidney, and spleen remainedWe explored whether XIAP antagonists could collaborate with
histologically normal. Also, these compounds did not induceconventional anticancer drugs to induce killing of tumor cells.
significant abnormalities in blood cell counts or serum chemis-Figure 5A presents representative data for Du145 prostate can-
tries at doses that were sufficient for antitumor activity (Figurecer cells, showing that XIAP antagonist 1396-34 significantly
increased dose-dependent cytotoxicity of Etoposide (VP16), Dox- S6 [http://www.cancercell.org/cgi/content/full/5/1/25/DC1]).
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Figure 6. IAP antagonists demonstrate antitumor activity in clonogenic survival assays and tumor xenograft studies
A: IAP antagonist 1396-34 inhibits clonogenic survival of cancer cells. Two prostate cancer lines were cultured with IAP antagonist 1396-34 for 3 days, then
culture medium was changed and colonies were counted 1 week later. Control compound is represented by the bars, showing only the 10 M dose
results.
B: Male Balb/C nu/nu mice were injected s.c with 2.5 million PPC1 prostate cancer cells (n  8). Half the animals received ip injections of 1396-34 in DMF
at 30 mg/kg at day 7 and day 8, while the other half received DMF diluent alone. Tumor growth was monitored at least twice weekly by external calipers
(mean  SE). (Inset) At 24 days after compound injections, mice were sacrificed and tumors were excised and weighed (mean 	 SE).
C: HCT-116 colon cancer cells (2.5  106) were injected subcutaneously in the flanks of female Balb/C nu/nu mice. On days 6, 7, and 8, when tumors
were 125 mm3, mice were treated with 30 mg/kg of XIAP inhibitor 1396-34 (I) (n  10) or solvent control (C) (n  19) by IP injection. On day 19, the mice
were sacrificed, the tumors excised and weighed. Differences in tumor size and weight on day 19 are significant by the rank sum test (p 
 0.001). Bars
represent the median tumor size or weight.
D and E: In vivo activation of Caspases in tumors by IAP antagonists. Tumor-bearing Balb/c mice (8 weeks age) were either injected i.p. for three successive
days with 30 mg/kg of polyphenylurea compound 1396-12 or with an equal volume of diluent alone (CNTL). Mice were sacrificed at 24 hr after the last
dose, and tumor tissue was analyzed either by (D) immunoblot analysis using an antibody specific for cleaved caspase-3 or actin or by (E) immunohistochemis-
try, using antibodies recognizing PCNA (blue stain [nuclei]) or the cleaved forms of Caspase-3, Caspase-6, and DFF40 (brown staining). The first panels (left)
represent H&E stained sections. A double-staining method was used to assess PCNA and cleaved Caspase 3 simultaneously.
Discussion other proteins of relevance to tumor biology. Many strategies
for restoring apoptosis sensitivity in refractory cancers have
been envisioned, and some are undergoing clinical testing inThe regulation of apoptosis is complex and multifaceted, with
multiple checkpoints for either enhancing or suppressing the humans. A potential advantage of IAPs as drug targets is that
they operate at a distal point in apoptosis pathways, potentiallycell death machinery. Caspases are the ultimate effectors of
apoptosis (Cryns and Yuan, 1999; Thornberry and Lazebnik, bypassing many upstream defects in apoptosis-regulatory
mechanisms in tumors. However, this strategy is only valid if1998). The activity of these intracellular proteases is countered
by certain IAP family proteins. Thus, IAPs define a distal check- tumor and normal cells demonstrate differential sensitivities to
IAP suppression.point for cell death control, downstream of p53, Bcl-2, and many
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In this report, we describe nonpeptidic, small-molecule in- fundamentally from the endogenous XIAP antagonist SMAC,
which is known to target BIR3 and overcome Caspase-9 sup-hibitors of the IAP family protein, XIAP, resulting from a screen
of nearly one million synthetic chemicals. At least eight active pression (Liu et al., 2000; Srinivasula et al., 2001; Wu et al., 2000).
Furthermore, the polyphenylurea-based XIAP antagonists docompounds were identified within a library of polyphenylureas,
the most active of which induce apoptosis of a broad range of not compete with SMAC peptides for binding to XIAP, adding
further weight to the evidence that they suppress XIAP throughtumor and leukemia cells in vitro as single agents, while having
comparatively little toxicity on normal cells. Moreover, a perfect a non-SMAC mechanism. It remains to be determined whether
the polyphenylurea-based compounds described here mimiccorrelation was observed between the inhibitory activity of these
compounds on XIAP in a Caspase-3 enzyme derepression assay the effects of other endogenous antagonists of XIAP, such as
XAF1 (Liston et al., 2001), versus suppressing XIAP through aand their ability to induce apoptosis of malignant cells in culture.
Cell death induction by XIAP antagonists was blocked by Cas- novel mechanism. It also remains formally possible that our
compounds bind an adjacent site in the SMAC tetrapeptidepase inhibitor zVAD-fmk and reduced by overexpressing XIAP
but unaffected by overexpression of upstream apoptosis sup- binding pocket of BIR domains, thus acting through an analo-
gous mechanism as SMAC but favoring BIR2 rather than BIR3pressors Bcl-XL and CrmA, which are characteristics consistent
with mechanism-based cytotoxicity. These compounds were of XIAP. Differences in the mechanism of XIAP inhibition by our
polyphenylurea-based compounds (which target the Caspase-also considerably less toxic against transformed xiap/ cells
lacking the intended drug target, further validating their mecha- 3-suppressing activity of XIAP) compared to previously de-
scribed SMAC peptides (which target the Caspase-9-suppressingnism. While this manuscript was in preparation, Wu et al. de-
scribed a structurally distinct class of XIAP antagonists (Wu et activity of XIAP) presumably explain why the small-molecule
antagonists described here induce apoptosis directly, whileal., 2003). However, the activity of those compounds against
endogenous XIAP in tumor cells in vitro or in vivo and their SMAC peptides generally sensitize tumor cells to apoptosis-
inducing agents but often fail to induce apoptosis as singletoxicity to normal cells were not determined.
The results obtained with our XIAP antagonists suggest that agents (Fulda et al., 2002; Yang et al., 2003b). The difficulties
of delivering peptides into cells could account for some of thecancer cells have an intrinsic drive to activate Caspases, such
that functional removal of IAPs permits apoptosis to occur. This bioactivity differences compared to our compounds, but even
membrane-penetrating SMAC-Arg8 failed to induce apoptosishypothesis is consistent with recent data showing evidence of
processed Caspase-3 in tumor cell lines and tumor tissues, of leukemia cells at concentrations 5–10 times higher than our
BIR2-targeting XIAP antagonists.offset by overexpression of XIAP or other IAP family members
(Yang et al., 2003a). In this regard, many causes of Caspase The human genome encodes eight IAP family proteins. While
all of these proteins contain BIR domains (by definition), theactivation in tumor cells can be envisioned, including protoonco-
gene activation, disobeyance of cell cycle checkpoints associ- mechanisms by which they suppress apoptosis vary. For exam-
ple, while XIAP, cIAP1, and cIAP2 have been demonstrated toated with defective DNA replication and chromosome segrega-
tion, and loss of cell attachment (anchorage-independent directly bind and suppress Caspase-3 in vitro (Deveraux et al.,
1997; Roy et al., 1997), inhibition of this Caspase by the IAPgrowth), all of which are known to drive apoptosis unless coun-
tered by antiapoptotic proteins (Evan and Vousden, 2001). In family member Survivin is controversial (Reed, 2001). Also, ML-
IAP may operate as a SMAC antagonist rather than as a Caspasecontrast, normal cells would be expected to have fewer drives
to Caspase activation, thus rendering them less dependent on inhibitor (Vucic et al., 2002). The inhibitory mechanisms for keep-
ing IAP family protein in check in vivo also vary, given thatIAPs—a notion supported by gene ablation studies in mice,
which have revealed little or no adverse phenotypes in animals SMAC binds XIAP but not Survivin (Marusawa et al., 2003). Thus,
it is unlikely that the polyphenylurea-based XIAP antagonistslacking XIAP, cIAP1, cIAP2, or NAIP (Harlin et al., 2001; Holcik
et al., 2000) (T. Mak, personal communication). described here are active against all IAP family proteins. Addi-
tional structure-activity relationship studies will define the reper-XIAP is the best-studied of the human IAP family proteins
from the standpoint of biochemical mechanism (Stennicke et toire of IAP family proteins that are affected by these com-
pounds, thus guiding future decisions about which types ofal., 2002), and its overexpression in several types of human
cancers has been documented (Ferreira et al., 2001; Hofmann cancer might be most sensitive to this structural class of antago-
nists. The potential for these compounds to inhibit other IAPet al., 2002; Krajewska et al., 2003; Tamm et al., 2000). XIAP
suppresses the downstream effector proteases Caspase-3 family members besides XIAP may account for the lack of corre-
lation of XIAP protein levels with EC50 in the NCI panel of 60and -7 via its BIR2 region, while suppressing upstream initiator
protease Caspase-9 via the BIR3 region (Deveraux et al., 1997, tumor cell lines (Tamm et al., 2000) (http://dtp.nci.nih.gov),
though other explanations also are possible, such as differences1999; Takahashi et al., 1998). Our objective was to search for
agents that overcome the inhibitory effect of XIAP on the effector among tumor cell lines in the ratio of XIAP to endogenous XIAP
antagonists (e.g., XAF1, SMAC, HtrA2) and regulation of XIAPproteases Caspase-3 and -7, favoring this strategy over screens
targeting the Caspase-9-suppressing activity of XIAP. The poly- by posttranslational modifications.
XIAP blocks apoptosis at a distal step in apoptosis path-phenylurea-based compounds described here overcome the
inhibitory effects of XIAP on Caspases-3 and -7 but not Cas- ways, at the convergence of cell death pathways activated by
mitochondria-dependent death stimuli (e.g., DNA-damagingpase-9 in vitro. Also, they are active against a fragment of XIAP
which is known to be sufficient for binding and inhibiting Cas- drugs; x-irradiation; growth factor deprivation) and by mitochon-
dria-independent TNF/Fas family death ligands (e.g., TNF, FasL,pase-3, comprised only of the BIR2 region with an accompa-
nying upstream flanking segment (Riedl et al., 2001; Sun et al., TRAIL). Consistent with this mechanism, we observed that
small-molecule antagonists of XIAP sensitized tumor cells to1999; Takahashi et al., 1998). The mechanism of these small-
molecule compounds remains to be elucidated, but they differ cell death induced by anticancer drugs as well as TNF family
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was measured with a plate reader (LJL analyst #1) using 360 nm excitationmember TRAIL. The ability of XIAP antagonists to collaborate
and 620 nm emission wavelengths with a dichroic mirror at 400 nm. For thewith a broad range of anticancer drugs in vitro raises the intri-
second assay, biotinylated SMAC 7-mer peptide (50 ng) was bound to 96-guing possibility of exploiting such compounds as chemosensi-
well plates coated with NeutrAvidin (Pierce, Rockford, IL) at 1 g/mL in 100
tizers for cancer therapy but requires further exploration with L per well of 50 mM HEPES (pH 7.4), 100 mM NaCL, 1 mM EDTA, 10%
respect to effects on sensitivity of normal cells to chemotherapy. sucrose, 0.1% CHAPS, 10 mM DTT. Then, GST-XIAP was added at 0.1 g/
The ability of polyphenylurea-based XIAP antagonists to sup- mL in 100L with or without chemical compounds in DMSO. After incubation
for 1 hr at room temperature, plates were washed with PBS with 0.05%press tumor growth in vivo in tumor xenograft models as single
Tween 20, and bound GST-XIAP was detected by addition of mouse anti-agents delivered at modest doses suggests that these chemical
GST monoclonal antibody (1:2000 dilution), followed by anti-mouse horse-compounds could serve as prototypes for drug development,
radish peroxidase (HRP)-conjugated IgG and 3,35,5-Tetramethylbenzidine
providing suitable toxicological and pharmacokinetic profiles Base (TMB) substrate, using a plate reader at 450 nm.
can be achieved. Regardless, the results provide validation of
IAPs as targets for cancer drug discovery based on a small- Cell culture
Tumor cell lines and primary cells were cultured in RPMI 1640, DMEM (high-molecule chemical strategy that seeks to overcome the ability
glucose), DMEM-H21, or IMDM medium, with 5%–10% fetal calf serumof these proteins to suppress downstream effector Caspases.
(FCS), 1 mM L-glutamine, and penicillin/streptomycin. Primary epithelial cells
were obtained from Cambrex (Walkersville, MD). Normal PBLs, bone marrowExperimental Procedures
mononuclear cells (BMMCs), and primary leukemia cells were isolated by
density centrifugation of samples from whole blood or bone marrow aspiratesCaspase derepression assay
obtained from either healthy donors or patients, with informed consent underRecombinant proteins were produced in bacteria and purified as described
IRB approval. AML blasts were verified by immunofluorescence flow cytome-(Deveraux et al., 1997; Stennicke and Salvesen, 1997; Takahashi et al.,
try to be composed of 80% CD-34-positive cells. PBLs and CLLs were1998). GST-XIAP (46 nM) or GST-BIR2 (1.2 nM) was added to active Cas-
verified to be comprised of 80% T cells and 95% B cells, respectively,pase-3-His6 (0.36 nM) (Stennicke and Salvesen, 1997) in 100 L of 50 mM
by flow cytometry. Chemical compounds were added to cultures in DMSO.HEPES (pH 7.4), 10% sucrose, 1 mM EDTA, 0.1% CHAPS, 100 mM NaCl,
Apoptosis-inducing agents included TRAIL (BioMol), Paciltaxel (Sigma, St.and 10 mM DTT to achieve 75% inhibition of protease activity. Recombi-
Louis, MO), Etoposide (Sigma), and Doxorubicin (Sigma).nant GST-XIAP (50 nM) was added to active (Card)Caspase 9 E306A (2.2
nM) (Stennicke et al., 1999). Activity of Caspase-3 and -9 was measured by
Cell death assaysmonitoring cleavage of the fluorogenic tetrapeptide substrates acetyl-Asp-
Various methods were employed to assess effects of XIAP antagonists onGlu-Val-Asp-AFC and acetyl-Leu-Glu-His-Asp-AFC (BIOMOL, Plymouth, PA) at
cell viability, including Annexin-V staining, MTT dye reduction, and Sulforho-100M, respectively. Generation of fluorogenic AFC (7-amino-4-trifluoromethyl
damine B staining, essentially as described (Alley et al., 1988; Dimitroulakoscoumarin) product was measured with a spectrofluorometric plate reader in
et al., 2001; Schimmer et al., 2003), in either 12-, 24-, or 96-well formats.kinetic mode for 30 min at 37C using excitation and emission wavelengths
For some experiments, Annexin-V staining was assessed using a 96-wellof 405 nm and 510 nm, respectively. Chemical compounds were screened
compatable flow cytometer (Guava Technologies, Inc.).at 6.25, 12.5, and 25.0 g/ml to identify compounds that increased Caspase-
3-induced cleavage of DEVD-AFC, setting a 2-fold rise in protease activity
Caspase activityas the threshold for positivity. Control reactions lacked XIAP, and all assays
To measure cellular Caspase activity, 104 cells per well were seeded intowere conducted in the linear range of substrate hydrolysis to avoid substrate
96-well flat-bottom black plates (Corning Inc, Corning, NY). Cells were thendepletion artifacts.
cultured 1 day later with the XIAP inhibitors or control compounds for 20
hr. Caspase-3 activity was detected by the addition of the cell-permeableChemical libraries
“CellProbe HT Caspase 3/7 substrate” according to the manufacturer’sEleven mixtured-based small-molecule combinatorial libraries constituting
instructions (Beckman Coulter, Palo Alto, CA). Assays were performed atapproximately one million compounds were screened. The library from which
1 hr after incubation with the Caspase-3 substrate, measuring release ofthe described XIAP inhibitors were identified was a polyphenylurea library
fluorescent rhodamine dye using a fMax spectrofluorimeter plate readercomposed of a total of 89,856 compound (Nefzi et al., 2000) synthesized in
(excitation at 485 nm and emission at 538 nm) (Sunnyvale, CA).the positional scanning format (Pinilla et al., 1992) with 48 functionalities at
the R1 and R2 positions and 39 functionalities at the R3 position using the
Clonogenic survival assayslibraries from libraries approach (Ostresh et al., 1994) (48  48  39 
Tumor cells (n  200) in RPMI with 10% FCS were seeded into 12-well89,856). Three separate sublibraries were synthesized representing the same
plates and cultured with polyphenylurea XIAP inhibitors or inactive controldiversity and differing solely by the location of the defined position, allowing
compounds for 3 days. The medium was then replaced, and cells werefor library deconvolution essentially as described (Pinilla et al., 1992, 2003).
cultured for 1 week before fixing with 4% paraformaldehyde and stainingIndividual compounds were synthesized by solid-phase methods, purified
with methylene blue and counting colonies. All assays were performed inby HPLC, and analyzed by mass-spectrometry to confirm identity and90%
triplicate (mean  SD).purity. Data for prototype active XIAP antagonists are based on more than
one independent preparations of purified individual compounds.
Cell transfections
For transient transfections, HeLa cells were transfected with pcDNA3 (con-SMAC peptide competition assay
trol) or pcDNA3-based plasmids encoding human XIAP, Bcl-XL, or CrmA,Two types of assays were developed. For the first assay, GST-XIAP or
using Lipofectamine Plus (Gibco-BRL, Carlsbad, CA), essentially as de-control protein GST-Bid at 1 M in PBS (pH 7.4) was adsorbed overnight
scribed (Deveraux et al., 1997, 1998). Cells were treated with the XIAPat 4C to 96-well flat-bottom black plates (Corning Inc, Corning, NY) using
inhibitors or control compounds in 
1% DMSO at 2 days after transfection.100 L per well. Plates were washed extensively with H20, then incubated
Stably transfected U937 cells were generously provided by D. Kufe (Danafor 1 hr with 0.01% gelatin in phosphate-buffered saline (pH 7.4) (PBS).
Farber; Boston). Expression was confirmed by immunoblotting.SMAC 7-mer (AVPIAQK), conjugated at the C terminus with biotin, was
added to the plates in 100 L of PBS containing 0.01% gelatin with or
without XIAP-inhibitory compounds in 1% (v:v) DMSO and incubated for Tumor xenografts
PPC1 or HCT116 (2.5 106) cells in 100L of RPMI were injected subcutane-2 hr at room temperature. Plates were then washed five times with H2O,
and 0.1 mL/well was added of a solution containing DELFIA assay buffer and ously into the flanks of male Balb-c nu/nu mice (Simonsen, Gilroy, CA)
age 4–6 weeks. At various times thereafter when tumors were 125 mm3Europium (EU)-conjugated Streptavidin (Perkin-Elmer). After 1 hr incubation,
plates were washed in H2O and 0.1 mL/well of Delphia Enhancement solution (day 6 or 7), mice were injected i.p. with 30 mg/kg of chemical compounds
or an equivalent volume of solvent diluent control (DMSO or DMF). The dosewas added and the plates were incubated for 15 min. EU-based fluorescence
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sis) proteins as predictors of response to chemotherapy in advanced non-was repeated the next day or for 2 additional days. Tumor size was measured
small-cell lung cancer patients. Ann. Oncol. 12, 799–805.at least twice weekly with calipers for approximately 3 weeks. Mice were
sacrificed by CO2 asphixiation at 19–24 days after tumor inoculation, tumor Fulda, S., Wick, W., Weller, M., and Debatin, K.M. (2002). Smac agonists
excised, and weighed. In some experiments, mice were sacrificed 24 hr sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce
after the last dose and tumor tissue was excised and either homogenized regression of malignant glioma in vivo. Nat. Med. 8, 808–815.
for immunoblot analysis or fixed and sectioned for histological analysis.
Gordon, G.J., Appasani, K., Parcells, J.P., Mukhopadhyay, N.K., Jaklitsch,Tissue sections were subjected either to hematoxylin-eosin staining or were
M.T., Richards, W.G., Sugarbaker, D.J., and Bueno, R. (2002). Inhibitor ofstained with antibodies specific for cleaved Caspase-3, Caspase-6, or
apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcino-DFF40, alone or in combination with anti-PCNA antibody. All animal experi-
genesis 23, 1017–1024.ments were conducted in accordance with the NIH guidelines under institu-
tional approval. Harlin, H., Reffey, S.B., Duckett, C.S., Lindsten, T., and Thompson, C.B.
(2001). Characterization of XIAP-deficient mice. Mol. Cell. Biol. 21, 3604–
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